Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

CCR5-Δ32 and IFNL4-ΔG/TT.

Jiang JJ, Fang MZ, Jackson SS, O'Brien TR.

Clin Ther. 2019 Nov 8. pii: S0149-2918(19)30500-4. doi: 10.1016/j.clinthera.2019.10.004. [Epub ahead of print] No abstract available.

PMID:
31711627
2.

Metabolic Changes in Chronic Hepatitis C Patients who Carry IFNL4-ΔG and Achieve Sustained Virologic Response with Direct-Acting Antiviral Therapy.

Emmanuel B, El-Kamary SS, Magder LS, Stafford KA, Charurat ME, Chairez C, McLaughlin M, Hadigan C, Prokunina-Olsson L, O'Brien TR, Masur H, Kottilil S.

J Infect Dis. 2019 Aug 26. pii: jiz435. doi: 10.1093/infdis/jiz435. [Epub ahead of print]

PMID:
31504644
3.

What makes the hepatitis C virus evolve?

O'Brien TR, Hartmann R, Prokunina-Olsson L.

Elife. 2019 Sep 3;8. pii: e50148. doi: 10.7554/eLife.50148.

4.

What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection?

O'Brien TR, Jackson SS.

J Interferon Cytokine Res. 2019 Oct;39(10):618-626. doi: 10.1089/jir.2019.0048. Epub 2019 Jun 4.

PMID:
31161939
5.

Meeting Overview: Interferon Lambda-Disease Impact and Therapeutic Potential.

O'Brien TR, Young HA, Donnelly RP, Prokunina-Olsson L.

J Interferon Cytokine Res. 2019 Oct;39(10):586-591. doi: 10.1089/jir.2019.0018. Epub 2019 Apr 17.

PMID:
30998425
6.

Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013.

Shiels MS, Engels EA, Yanik EL, McGlynn KA, Pfeiffer RM, O'Brien TR.

Cancer. 2019 Aug 1;125(15):2621-2630. doi: 10.1002/cncr.32129. Epub 2019 Apr 12.

PMID:
30980394
7.

Prediagnostic serum organochlorine insecticide concentrations and primary liver cancer: A case-control study nested within two prospective cohorts.

Engel LS, Zabor EC, Satagopan J, Widell A, Rothman N, O'Brien TR, Zhang M, Van Den Eeden SK, Grimsrud TK.

Int J Cancer. 2019 Nov 1;145(9):2360-2371. doi: 10.1002/ijc.32175. Epub 2019 Feb 14.

PMID:
30701531
8.

Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia.

Mahale P, Aka P, Chen X, Pfeiffer RM, Liu P, Groover S, Mendy M, Njie R, Goedert JJ, Kirk GD, Glenn JS, O'Brien TR.

J Viral Hepat. 2019 Jun;26(6):738-749. doi: 10.1111/jvh.13065. Epub 2019 Feb 14.

PMID:
30661282
9.

Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.

Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Latanich R, Wojcik GL, Taub MA, Valencia A, Thomas DL, Duggal P.

Gastroenterology. 2019 Apr;156(5):1496-1507.e7. doi: 10.1053/j.gastro.2018.12.014. Epub 2018 Dec 26.

PMID:
30593799
10.

Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression.

O'Brien TR, Yang HI, Groover S, Jeng WJ.

Gastroenterology. 2019 Jan;156(2):400-417. doi: 10.1053/j.gastro.2018.09.052. Epub 2018 Oct 1. Review.

PMID:
30287169
11.

Impact of IFNL4-∆G genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals.

Backus LI, Shahoumian TA, Belperio PS, Winters M, Prokunina-Olsson L, O'Brien TR, Holodniy M.

Diagn Microbiol Infect Dis. 2018 Sep;92(1):34-36. doi: 10.1016/j.diagmicrobio.2018.04.004. Epub 2018 Apr 14.

PMID:
29866411
12.

Hepatitis D Viremia Among Injection Drug Users in San Francisco.

Mahale P, Aka PV, Chen X, Liu P, Fram BJ, Wang AS, Simenel S, Tseng FC, Chen S, Edlin BR, Glenn JS, O'Brien TR.

J Infect Dis. 2018 May 25;217(12):1902-1906. doi: 10.1093/infdis/jiy157.

13.

Beasley's 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention.

Koshiol J, Liu Z, O'Brien TR, Hildesheim A.

Cancer Epidemiol. 2018 Apr;53:195-199. doi: 10.1016/j.canep.2018.01.007. Epub 2018 Feb 13. Review.

14.

Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus.

Mahale P, Glenn JS, O'Brien TR.

Ann Intern Med. 2017 Nov 21;167(10):759-760. doi: 10.7326/L17-0476. No abstract available.

PMID:
29159388
15.

The role of genetics in hepatic fibrosis among hepatitis C virus patients.

Park H, O'Brien TR, Rehermann B.

Hepatology. 2018 May;67(5):2043-2045. doi: 10.1002/hep.29659. Epub 2018 Mar 25. No abstract available.

PMID:
29152758
16.

IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir.

O'Brien TR, Kottilil S, Pfeiffer RM.

Gastroenterology. 2017 Dec;153(6):1694-1695. doi: 10.1053/j.gastro.2017.06.069. Epub 2017 Nov 3. No abstract available.

PMID:
29107709
17.

Shortening the duration of therapy for chronic hepatitis C infection.

Emmanuel B, Wilson EM, O'Brien TR, Kottilil S, Lau G.

Lancet Gastroenterol Hepatol. 2017 Nov;2(11):832-836. doi: 10.1016/S2468-1253(17)30053-5. Epub 2017 Aug 10. Review.

18.

Relationship of Genotype for HLA B*57 and IFNL4 With Disease Progression in Female HIV Controllers.

Kuniholm MH, Strickler HD, Anastos K, Prokunina-Olsson L, Aouizerat BE, O'Brien TR.

Clin Infect Dis. 2017 Oct 1;65(7):1243-1244. doi: 10.1093/cid/cix481. No abstract available.

19.

Race or genetic makeup for hepatitis C virus treatment decisions?

O'Brien TR, Kottilil S, Feld JJ, Morgan TR, Pfeiffer RM.

Hepatology. 2017 Jun;65(6):2124-2125. doi: 10.1002/hep.29057. Epub 2017 Apr 18. No abstract available.

20.

Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials.

Loftfield E, O'Brien TR, Pfeiffer RM, Howell CD, Horst R, Prokunina-Olsson L, Weinstein SJ, Albanes D, Morgan TR, Freedman ND.

PLoS One. 2016 Nov 10;11(11):e0166036. doi: 10.1371/journal.pone.0166036. eCollection 2016.

21.

Association of Hepatitis C Virus Infection With CD4/CD8 Ratio in HIV-Positive Women.

Kuniholm MH, OʼBrien TR, Prokunina-Olsson L, Augenbraun M, Plankey M, Karim R, Sarkar M, French AL, Pierce C, Strickler HD, Anastos K.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):162-70. doi: 10.1097/QAI.0000000000000928.

22.

Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C.

O'Brien TR, Pfeiffer RM.

Open Forum Infect Dis. 2015 Apr 20;2(2):ofv057. doi: 10.1093/ofid/ofv057. eCollection 2015 Apr. No abstract available.

23.

No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL.

O'Brien TR, Feld JJ, Kottilil S, Pfeiffer RM.

Hepatology. 2016 Jan;63(1):28-30. doi: 10.1002/hep.28292. Epub 2015 Nov 25. No abstract available.

24.

Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes.

Lang Kuhs KA, Kuniholm MH, Pfeiffer RM, Chen S, Desai S, Edlin BR, Peters MG, Plankey M, Sharp GB, Strickler HD, Villacres MC, Quinn TC, Gange SJ, Prokunina-Olsson L, Greenblatt RM, O'Brien TR.

PLoS One. 2015 Oct 2;10(10):e0138827. doi: 10.1371/journal.pone.0138827. eCollection 2015.

25.

Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.

O'Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, Edlin BR, Howell CD, Kirk GD, Kuniholm MH, Morgan TR, Strickler HD, Thomas DL, Prokunina-Olsson L.

J Hepatol. 2015 Nov;63(5):1103-10. doi: 10.1016/j.jhep.2015.06.035. Epub 2015 Jul 15.

26.

Association of IFNL3 and IFNL4 polymorphisms with liver-related mortality in a multiracial cohort of HIV/HCV-coinfected women.

Sarkar M, Aouzierat B, Bacchetti P, Prokunina-Olsson L, French A, Seaberg E, O'Brien TR, Kuniholm MH, Minkoff H, Plankey M, Strickler HD, Peters MG; Women's Interagency HIV.

J Viral Hepat. 2015 Dec;22(12):1055-60. doi: 10.1111/jvh.12431. Epub 2015 Jun 26.

27.

Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C.

O'Brien TR, Lang Kuhs KA, Pfeiffer RM.

Open Forum Infect Dis. 2014 Dec 13;1(3):ofu110. doi: 10.1093/ofid/ofu110. eCollection 2014 Dec.

28.

Use of computer and cellular phone technology by older rural adults.

O'Brien TR, Treiber F, Jenkins C, Mercier A.

Comput Inform Nurs. 2014 Aug;32(8):390-6. doi: 10.1097/CIN.0000000000000080.

PMID:
24949713
29.

The plant beneficial effects of Metarhizium species correlate with their association with roots.

Liao X, O'Brien TR, Fang W, St Leger RJ.

Appl Microbiol Biotechnol. 2014 Aug;98(16):7089-96. doi: 10.1007/s00253-014-5788-2. Epub 2014 May 8.

PMID:
24805846
30.

IFN-λ4: the paradoxical new member of the interferon lambda family.

O'Brien TR, Prokunina-Olsson L, Donnelly RP.

J Interferon Cytokine Res. 2014 Nov;34(11):829-38. doi: 10.1089/jir.2013.0136. Epub 2014 Apr 30. Review.

31.

IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.

Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, O'Brien TR, Herrmann E, Kottilil S, Osinusi A.

J Infect Dis. 2014 Jun 1;209(11):1700-4. doi: 10.1093/infdis/jit827. Epub 2013 Dec 23.

32.

Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.

Wang AS, Pfeiffer RM, Morgan TR, O'Brien TR.

Hepatology. 2014 Jun;59(6):2423-4. doi: 10.1002/hep.26771. Epub 2014 Apr 14. No abstract available.

33.

Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus.

Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, Astemborski J, Plankey M, Villacres MC, Peters MG, Desai S, Seaberg EC, Edlin BR, Strickler HD, Thomas DL, Prokunina-Olsson L, Sharp GB, O'Brien TR.

J Infect Dis. 2014 Feb 1;209(3):350-4. doi: 10.1093/infdis/jit433. Epub 2013 Aug 15.

34.

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR.

Nat Genet. 2013 Feb;45(2):164-71. doi: 10.1038/ng.2521. Epub 2013 Jan 6.

35.

Observation of well-ordered metastable vortex lattice phases in superconducting MgB2 using small-angle neutron scattering.

Das P, Rastovski C, O'Brien TR, Schlesinger KJ, Dewhurst CD, DeBeer-Schmitt L, Zhigadlo ND, Karpinski J, Eskildsen MR.

Phys Rev Lett. 2012 Apr 20;108(16):167001. Epub 2012 Apr 19.

PMID:
22680750
36.

HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations.

Uccellini L, Tseng FC, Monaco A, Shebl FM, Pfeiffer R, Dotrang M, Buckett D, Busch MP, Wang E, Edlin BR, Marincola FM, O'Brien TR.

Hepatology. 2012 Jul;56(1):86-94. doi: 10.1002/hep.25652. Epub 2012 Jun 1.

37.

Local adaptation of an introduced transgenic insect fungal pathogen due to new beneficial mutations.

Wang S, O'Brien TR, Pava-Ripoll M, St Leger RJ.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20449-54. doi: 10.1073/pnas.1113824108. Epub 2011 Dec 5.

38.

Editorial: epidemic-assistance investigations by the centers for disease control and prevention: the first 60 years.

O'Brien TR.

Am J Epidemiol. 2011 Dec 1;174(11):1211-2. doi: 10.1093/aje/kwr336. No abstract available.

39.

IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association.

Shebl FM, Pfeiffer RM, Buckett D, Muchmore B, Chen S, Dotrang M, Prokunina-Olsson L, Edlin BR, O'Brien TR.

J Infect Dis. 2011 Dec 15;204(12):1843-7. doi: 10.1093/infdis/jir647. Epub 2011 Oct 19.

40.

Interferon-lambda and therapy for chronic hepatitis C virus infection.

Donnelly RP, Dickensheets H, O'Brien TR.

Trends Immunol. 2011 Sep;32(9):443-50. doi: 10.1016/j.it.2011.07.002. Epub 2011 Aug 5. Review.

41.

An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.

O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM; HALT-C Trial Group.

PLoS One. 2011;6(7):e20904. doi: 10.1371/journal.pone.0020904. Epub 2011 Jul 8.

42.

A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.

Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT; HALT-C Trial Group.

Gastroenterology. 2011 Jul;141(1):141-9. doi: 10.1053/j.gastro.2011.03.045. Epub 2011 Mar 24.

43.

Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver.

O'Brien TR, Kohaar I, Pfeiffer RM, Maeder D, Yeager M, Schadt EE, Prokunina-Olsson L.

Genes Immun. 2011 Sep;12(6):428-33. doi: 10.1038/gene.2011.11. Epub 2011 Feb 24.

44.

IL28B-genotype testing now and in the era of direct-acting antiviral agents.

Morgan TR, O'Brien TR.

Clin Gastroenterol Hepatol. 2011 Apr;9(4):293-4. doi: 10.1016/j.cgh.2010.12.014. Epub 2010 Dec 23. No abstract available.

45.

In the absence of HCV infection, interferon stimulated gene expression in liver is not associated with IL28B genotype.

Shebl FM, Maeder D, Shao Y, Prokunina-Olsson L, Schadt EE, O'Brien TR.

Gastroenterology. 2010 Oct;139(4):1422-4. doi: 10.1053/j.gastro.2010.07.055. Epub 2010 Aug 25. No abstract available.

PMID:
20800110
46.

HLA-B alleles associate consistently with HIV heterosexual transmission, viral load, and progression to AIDS, but not susceptibility to infection.

Gao X, O'Brien TR, Welzel TM, Marti D, Qi Y, Goedert JJ, Phair J, Pfeiffer R, Carrington M.

AIDS. 2010 Jul 31;24(12):1835-40. doi: 10.1097/QAD.0b013e32833c3219.

47.

Splicing diversity of the human OCLN gene and its biological significance for hepatitis C virus entry.

Kohaar I, Ploss A, Korol E, Mu K, Schoggins JW, O'Brien TR, Rice CM, Prokunina-Olsson L.

J Virol. 2010 Jul;84(14):6987-94. doi: 10.1128/JVI.00196-10. Epub 2010 May 12.

48.

Interferon-alfa, interferon-lambda and hepatitis C.

O'Brien TR.

Nat Genet. 2009 Oct;41(10):1048-50. doi: 10.1038/ng.453. Epub 2009 Sep 13. No abstract available.

PMID:
19749756
49.

Genetic variation in CLDN1 and susceptibility to hepatitis C virus infection.

Bekker V, Chanock SJ, Yeager M, Hutchinson AA, von Hahn T, Chen S, Xiao N, Dotrang M, Brown M, Busch MP, Edlin BR, Rice CM, O'Brien TR.

J Viral Hepat. 2010 Mar;17(3):192-200. doi: 10.1111/j.1365-2893.2009.01166.x. Epub 2009 Aug 7.

50.

Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases.

Khoury MJ, Bertram L, Boffetta P, Butterworth AS, Chanock SJ, Dolan SM, Fortier I, Garcia-Closas M, Gwinn M, Higgins JP, Janssens AC, Ostell J, Owen RP, Pagon RA, Rebbeck TR, Rothman N, Bernstein JL, Burton PR, Campbell H, Chockalingam A, Furberg H, Little J, O'Brien TR, Seminara D, Vineis P, Winn DM, Yu W, Ioannidis JP.

Am J Epidemiol. 2009 Aug 1;170(3):269-79. doi: 10.1093/aje/kwp119. Epub 2009 Jun 4.

Supplemental Content

Loading ...
Support Center